Evaluation of disease activity in a low-income juvenile idiopathic arthritis cohort
- 108 Downloads
Determine disease activity in a low income juvenile idiopathic arthritis (JIA) cohort. 164 JIA patients from families with less than US$ 4500.00/capita mean annual income followed in Fortaleza-CE, Brazil, were cross-sectionally evaluated between May 2015–April 2016. Mean age was 14 ± 5.1 years (95 female) with 10.31 ± 3.7 years disease duration. Polyarticular category predominated, with 63 (38.4%) patients, followed by 40 (24%) enthesitis-related (ERA), and 36 (22%) oligoarticular. All but 1 out of 84 parents declared less than US$ 10,000.00 annual family income. Eighty-eight (60.7%) were receiving methotrexate and 19 (13%) leflunomide including 12 (63%) using both; 46 (28%) were on biologic DMARD including 20 (43.5%) adalimumab, 17 (41.5) etanercept, 5 (10.8%) tocilizumab, 2 (4.2%) abatacept, and 1 (2.1%) each on infliximab and canakinumab. Mean CHAQ and JADAS27 were 0.36 ± 0.55 and 5.31 ± 8.5, respectively. Thirty-two (20%) out of 159 patients had deformities. A bivariate analysis revealed that polyarticular had more deformities than oligoarticular patients (p = 0.002; OR = 2.389; 95% CI 1.37–4.14). Logistic regression showed no association between high JADAS and family income (p = 0.339; OR = 1.45; 95% CI 0.67–3.31). A general linear model showed significantly lower CHAQ score in patients from families earning more as compared to those earning less than 300.00 US$ monthly (p = 0.002). This study reports JIA disease activity in a low income population. Low income apparently did not influence prognosis given the low mean JADAS27 and CHAQ scores vis-à-vis data from other cohorts.
KeywordsJuvenile idiopathic arthritis Epidemiology Pediatric rheumatology
FACR and CNRJ conceived the article. FACR, JIVDL, LNR and HALR performed tabulation of data and statistics. JIVDL, MGA, JPEA, CNL, LHAC, LNR performed data collection, revision of clinical files, interviewed and applied questionnaires to patients/parents. All authors participated in the preparation and revision of the manuscript, read and approved the final version to be submitted.
This work was financially supported by Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPQ), Brasil—Grant 459334/2014-0.
Compliance with ethical standards
Conflict of interest
All authors declare that they have no competing interests.
- 1.Manners PJ, Bower C (2002) Worldwide prevalence of juvenile arthritis why does it vary so much? J Rheumatol 29:1520–1530Google Scholar
- 6.World Health Organization (2011) 10 facts on health inequities and their causes. World Health Organization, GenevaGoogle Scholar
- 10.Gutiérrez-Suárez R, Pistorio A, Cespedes Cruz A, Norambuena X, Flato B, Rumba I, Harjacek M, Nielsen S, Susic G, Mihaylova D, Huemer C, Melo-Gomes J, Andersson-Gare B, Balogh Z, De Cunto C, Vesely R, Pagava K, Romicka AM, Burgos-Vargas R, Martini A, Ruperto N; Pediatric Rheumatology International Trials Organisation (PRINTO) (2007) Health-related quality of life of patients with juvenile idiopathic arthritis coming from 3 different geographic areas. The PRINTO multinational quality of life cohort study. Rheumatology 46:314–320CrossRefGoogle Scholar
- 16.Machado CS, Ruperto N, Silva CH, Ferriani VP, Roscoe I, Campos LM, Oliveira SK, Kiss MH, Bica BE, Sztajnbok F, Len CA, Melo-Gomes JA (2001) The Brazilian version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ). Paediatric Rheumatology International Trials Organisation. Clin Exp Rheumatol 19(4 Suppl 23):S25–S29Google Scholar
- 18.Beukelman T, Kimura Y, Ilowite NT, Mieszkalski K, Natter MD, Burrell G, Best B, Jones J, Schanberg LE, CARRA Registry Investigators (2017) The new Childhood Arthritis and Rheumatology Research Alliance (CARRA) registry: design, rationale, and characteristics of patients enrolled in the first 12 months. Pediatr Rheumatol Online J 15:30–39CrossRefGoogle Scholar
- 22.Consolaro A, Negro G, Lanni S, Solari N, Martini A, Ravelli A (2012) Toward a treat-to-target approach in the management of juvenile idiopathic arthritis. Clin Exp Rheumatol 30:S157–S162Google Scholar